Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy

Fig. 4

The relationship between vimentin+ CTCs and PFS/OS in advanced CRC. The captured tumor cells were stained with anti-CK8/18/19 antibody for epithelial marker (green fluorescence), anti-vimentin antibody for mesenchymal marker (yellow fluorescence), anti-CD45 antibody for leukocytes (red fluorescence), and hoechst for nucleus (blue fluorescence). The CTM detected in peripheral blood of patients were CK+/Vimentin+/CD45− (a) or CK−/Vimentin+/CD45− (b) phenotype. The isolated CTCs were CK−/Vimentin+/CD45− (c) and CK+/Vimentin−/CD45− (d) phenotype. e, f Patients with vimentin+ CTCs had worse PFS/OS compared with CK+ CTCs (P = 0.0314, P = 0.0147)

Back to article page